SCHEMBL1046271

SCHEMBL1046271

Nc1ccc(OC(F)(F)F)cc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.53
KDM4E B2RXH2 3/20 0.52
KMT2A Q03164 2/20 0.52
GFER P55789 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
PIM1 P11309 1/20 0.51
MEN1 O00255 1/20 0.50
USP2 O75604 1/20 0.50
POLB P06746 1/20 0.50
MAPT P10636 1/20 0.50
THRB P10828 1/20 0.50
PKM P14618 1/20 0.50
APEX1 P27695 1/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
MCL1 Q07820 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
IGF2BP2 Q9Y6M1 1/20 0.49
GLA P06280 1/20 0.49
AKR1C2 P52895 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27647270 0.98 KMT2A (0.53) KEAP1KDM4EKMT2AGFERRXFP1
SCHEMBL14480999 0.87 KMT2A (0.64) KEAP1KDM4EKMT2AGFERRXFP1
SCHEMBL4091950 0.86 CHEK1 (0.47) KDM4EKMT2APIM1USP2PKM
SCHEMBL22497443 0.86 ALDH1A1 (0.57) KEAP1KDM4EKMT2APIM1TDP1
SCHEMBL30951611 0.85 PIM1 (0.43) KDM4EKMT2APIM1MEN1USP2
SCHEMBL13043978 0.85 PIM1 (0.43) KDM4EKMT2APIM1MEN1USP2
SCHEMBL18534954 0.84 PIM1 (0.43) KEAP1KDM4EKMT2APIM1USP2
SCHEMBL2824553 0.84 MAPT (0.57) PIM1POLBMAPTIGF2BP2ALDH1A1
SCHEMBL1438883 0.83 KDM4E (0.55) KDM4EKMT2APIM1MAPTGLA
SCHEMBL5158868 0.81 AKR1C2 (0.52) KDM4EKMT2APIM1MEN1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119350354-A Preparation of 10-trifluoro methoxy camptothecine derivative and application thereof in anti-tumor aspect 兰州大学 2025-01-24 CN claimed
CN-122036604-A Compound and application thereof 中国药科大学 2026-05-15 CN disclosed
EP-4731216-A1 HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS Augustine Therapeutics (BE) 2026-04-29 EP disclosed
US-12538924-B2 Pesticidally active heterocyclic derivatives with sulfur containing substituents SYNGENTA CROP PROTECTION AG (CH) 2026-02-03 US disclosed
EP-4204409-B1 PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS SYNGENTA CROP PROTECTION AG (CH) 2025-12-24 EP disclosed
EP-4596546-A1 SULFONAMIDE COMPOUND, AND HARMFUL-ARTHROPOD EXTERMINATION COMPOSITION CONTAINING SAME Sumitomo Chemical Company, Limited (JP) 2025-08-06 EP disclosed
CN-119998283-A Sulfonamide compound and harmful arthropod control composition containing same 住友化学株式会社 2025-05-13 CN disclosed
CN-119977893-A Preparation method and application of sulfonamide compound for antagonizing NOD1 清华大学 2025-05-13 CN disclosed
CN-113811532-B Pesticidally active heterocyclic derivatives with sulfur containing substituents 先正达农作物保护股份公司 2025-04-11 CN disclosed
CN-119350354-A Preparation of 10-trifluoro methoxy camptothecine derivative and application thereof in anti-tumor aspect 兰州大学 2025-01-24 CN disclosed
EP-1000067-A1 THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME Aventis Pharma S.A. (FR) 2000-05-17 EP disclosed
WO-2000023433-A1 SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 2000-04-27 WO disclosed
US-6034256-A CYCLOOXYGEASE INHIBITOR G.D. SEARLE & CO. (US) 2000-03-07 US disclosed
EP-0977748-A1 SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 2000-02-09 EP disclosed
WO-1999005147-A1 THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME RHONE-POULENC RORER S.A. (FR) 1999-02-04 WO disclosed
WO-1998047890-A1 SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1998-10-29 WO disclosed
US-5457105-A anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) ZENECA LIMITED (GB) 1995-10-10 US disclosed
US-4585772-A Agents for combating circulatory illnesses and their use BAYER AKTIENGESELLSCHAFT (DE) 1986-04-29 US disclosed
EP-0053767-B1 TRICYCLIC CYTOSINE DERIVATIVES FOR USE IN PHARMACEUTICAL PREPARATIONS AND PROCESS FOR THEIR PREPARATION BAYER AG (DE) 1984-09-12 EP disclosed
EP-0053767-A1 Tricyclic cytosine derivatives for use in pharmaceutical preparations and process for their preparation BAYER AG (DE) 1982-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12538924-B2 Pesticidally active heterocyclic derivatives with sulfur containing substituents CBR3, CBR1, CYCS KEAP1 8/4885KDM4E 1249/4885KMT2A 1795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.